Bortezomib Active Not Recruiting Phase 2 Trials for Acute Myelogenous Leukaemia (AML) Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01736943Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia